Diabetes Care, Vol 3, Issue 2 351-358, Copyright © 1980 by American Diabetes Association

ARTICLES

A totally implantable drug infusion defice: laboratory and clinical experience using a model with single flow rate and new design for modulated insulin infusion

H Buchwald, TD Rohde, FD Dorman, JG Skakoon, BD Wigness, FR Prosl, EM Tucker, TG Rublein, PJ Blackshear and RL Varco

The Infusaid implantable infusion pump with a single delivery rate has maintained chronic intravenous heparin infusion in man for greater than 35 mo and for greater than 5 yr in the dog. Intra-arterial infuson of fluorodeoxyuridine has been maintained for greater than 8 mo in man. In a pilot study using a commercially available, transcutaneously controllable, magnetically activated valve for baseline superimposed bolus insulin infusion, the feasibility of maintaining near normal serum glucose in diabetic dogs was demonstrated. The effect of long-term intravenous cannulation was investigated; it was found that the intimal tissues of the vena cava surrounding the cannulae were largely unaltered and microemboli could not be detected in the lungs of the animals studied. Cannula plugging, which occurred on several occasions due to thrombus formation in the final centimeter of the cannula, has been solved by changes in pump design and refilling procedures. The problem of insulin precipitation in flow passages of the pump remains unsolved, but there are indications that substances entering the cannula from the blood may be involved. A new pump design for modulated insulin infusion is described.
CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				R. Farkas-Hirsch and Lucya. Levandoski Implementation of Continuous Subcutaneous Insulin Infusion Therapy: An Overview The Diabetes Educator, January 1, 1988; 14(5): 401 - 406. [PDF]